Gibson Dunn has advised ERock, Inc. Davis Polk & Wardwell has advised the underwriters. ERock, Inc., a provider of large-scale onsite power solutions, has launched the...
ERock Launches Initial Public Offering on NYSE
Galecto Closes $316 Million Public Offering of Common Stock
Gibson Dunn has advised Galecto, Inc. Cooley LLP has advised the underwriters. Goodwin Procter LLP acted as intellectual property counsel for Galecto, Inc. Galecto, Inc. (Nasdaq:...
Yarrow Bioscience to Merge with VYNE Therapeutics in All-Stock Transaction
Gibson, Dunn & Crutcher LLP has advised Yarrow Bioscience. Cooley LLP has advised VYNE Therapeutics. Yarrow Bioscience and VYNE Therapeutics have entered into a definitive merger...
Cogent Biosciences Announces $230 Million Convertible Senior Notes Offering
Gibson Dunn has represented Cogent Biosciences, Inc., and Mintz has advised the underwriters. Cogent Biosciences, Inc. (Nasdaq: COGT) has announced the pricing of its underwritten public...
Cogent Biosciences Completes $345 Million Common Stock Offering and $200 Million Convertible Notes Offering
Gibson Dunn has represented Cogent Biosciences, Inc., Mintz has advised the underwriters. Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for...
X4 Pharmaceuticals Completes $155.3 Million Public Offering of Common Stock
Gibson, Dunn & Crutcher LLP has advised X4 Pharmaceuticals, and Freshfields US LLP has advised the underwriters. Dechert LLP has served as special counsel for X4...
HS Sawmill LP Launches $110 Million Secondaries Acquisition Vehicle Backed by Institutional Investors
Proskauer has advised Hudson Structured Capital Management on the closing of the HS Sawmill LP secondaries acquisition vehicle. Hudson Structured Capital Management (HSCM), operating as HSCM...
Bausch Health’s $7.9 Billion Refinancing Transaction
Proskauer and Squire Patton Boggs advised Bausch Health Companies Inc. on the transaction. Bausch Health Companies Inc. (NYSE: BHC) (TSX: BHC) (“Bausch Health”) announced its $7.9 billion...
89bio Inc.’s $125 Million Common Stock Offering
Gibson, Dunn & Crutcher advised 89bio, Inc. on the offering, and Cooley advised the underwriters. 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company, announced the...
Jade Biosciences’ Merger with Aerovate Therapeutics
Gibson, Dunn & Crutcher advised Jade Biosciences on the transaction, and Cooley advised the placement agents; while Goodwin Procter advised Aerovate Therapeutics, Inc. Aerovate Therapeutics, Inc....
Apogee Therapeutics’ $483 Million Common Stock Offering
Gibson, Dunn & Crutcher represented Apogee Therapeutics, Inc. in the offering, and Cooley represented the underwriters. Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company, announced the...